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Background: The stimulant methylphenidate (MPH) has been a mainstay of treatment for attention-deficit/hyperactivity
disorder (ADHD) for many years. Owing to the short half-life and the issues associated with multiple daily dosing of
immediate-release MPH formulations, a new generation of long-acting MPH formulations has emerged. Direct
head-to-head studies of these long-acting MPH formulations are important to facilitate an evaluation of their
comparative pharmacokinetics and efficacy; however, to date, relatively few head-to-head studies have been performed.
The objective of this systematic review was to compare the evidence available from head-to-head studies of long-acting
MPH formulations and provide information that can guide treatment selection.
Methods: A systematic literature search was conducted in MEDLINE and PsycINFO in March 2012 using the MeSH terms:
attention deficit disorder with hyperactivity/drug therapy; methylphenidate/therapeutic use and All Fields: Concerta;
Ritalin LA; OROS and ADHD; Medikinet; Equasym XL and ADHD; long-acting methylphenidate; Diffucaps and ADHD;
SODAS and methylphenidate. No filters were applied and no language, publication date or publication status limitations
were imposed. Articles were selected if the title indicated a comparison of two or more long-acting MPH preparations in
human subjects of any age; non-systematic review articles and unpublished data were not included.
Results: Of 15,295 references returned in the literature search and screened by title, 34 articles were identified
for inclusion: nine articles from pharmacokinetic studies (nine studies); nine articles from laboratory school
studies (six studies); two articles from randomized controlled trials (two studies); three articles from switching
studies (two studies) and three articles from one observational study.
Conclusions: Emerging head-to-head studies provide important data on the comparative efficacy of the
formulations available. At a group level, efficacy across the day generally follows the pharmacokinetic profile of
the MPH formulation. No formulation is clearly superior to another; careful consideration of patient needs and
subtle differences between formulations is required to optimize treatment. For patients achieving suboptimal
symptom control, switching long-acting MPH formulations may be beneficial. When switching formulations, it is
usually appropriate to titrate the immediate-release component of the formulation; a limitation of current
studies is a focus on total daily dose rather than equivalent immediate-release components. Further studies are
necessary to provide guidance in clinical practice, particularly in the treatment of adults and pre-school children
and the impact of comorbidities and symptom severity on treatment response.
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Attention-deficit/hyperactivity disorder (ADHD) is the
most common neurobehavioural disorder in childhood,
affecting approximately 5% of children worldwide and
persisting into adulthood in a majority of cases [1,2].
Stimulant medication, including methylphenidate (MPH),
is a mainstay of treatment for ADHD in children, adoles-
cents and adults [2,3]. Owing to the short half-life of MPH
and the varied issues associated with multiple daily dosing
of immediate-release MPH formulations (for example,
social stigma, reduced compliance, inconvenience and
security issues associated with controlled substances in
the school or workplace), a new generation of long-acting
MPH formulations has emerged (see Table 1 for a summary
of MPH formulations and synonyms) [4].
Most of these newer long-acting MPH formulations
differ from the first-generation, wax-matrix, continuous-
release preparation (Ritalin SRW; Novartis Pharmaceut-
ical Corporation, East Hanover, New Jersey, USA [5]) by
including an immediate-release component that en-
sures a rapid onset of action as well as an extended-Table 1 Summary of long-acting methylphenidate (MPH) form
MPH formulation Synonyms Product availability
BiphentinW [10] MPH ER Canada







DaytranaW [13] MPH transdermal system;
MethyPatch; MTS
USA
Equasym XLW [11] Equasym DepotW; Equasym
RetardW, Equasym XRW, Quasym
LPW; Metadate CDW; Metadate ERW
Europeg, South Kore
USA








Ritalin LAW [6] Ritalin LPW; Miacalcic France, Chile, USAh
Ritalin SRW [5] n/a Canada, USAh
aDuration of action as stated in the prescribing information.
bBotswana, Brazil, Egypt, Namibia, Nicaragua, South Africa.
cBahrain, China, Hong Kong, Indonesia, Israel, Japan, Jordan, Republic of Korea, Kuw
Taiwan Province of China, United Arab Emirates, Yemen.
dAustria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germ
Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden,
eBahamas, Barbados, Canada, Cayman Islands, Dominican Republic, El Salvador, Gua
fArgentina, Aruba, Bolivia, Chile, Columbia, Costa Rica, Ecuador, Panama, Paraguay,
gDenmark, Finland, France, Germany, Ireland, the Netherlands, Norway, Sweden, Sw
hInformation obtained from Thomson Cortellis™.
iAustria, Belgium, Cyprus, Denmark, Estonia, Finland, France, Germany, Ireland, Italy,
Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK.
jArgentina, El Salvador, Guatemala, Honduras.release component that continues to act throughout the
course of the day. This allows for rapid onset of action
with once-daily dosing while avoiding the need to take a
second dose of medication during the school or work day.
The various MPH formulations use different technolo-
gies that aim to provide symptom control for at least
8 hours and also incorporate differing proportions of
immediate- and extended-release MPH. As a conse-
quence, the immediate-release MPH bolus of the new
formulations ranges from 22 to 50% of the total MPH
dose. Ritalin LAW and Focalin XRW (both Novartis Pharma-
ceutical Corporation, East Hanover, New Jersey, USA) use
Spheroidal Oral Drug Absorption System (SODASW) tech-
nology to provide 50% of the MPH dose immediately and
50% as extended release [6,7]. Like most MPH formula-
tions, Ritalin LAW contains racemic MPH comprising
both the d-MPH and the l-MPH isomers; however, as
when taken orally the l-isomer is metabolized rapidly
via first pass through the hepatic circulation it is consid-
ered that the d-isomer is likely to be the main pharmaco-
















Transdermal patch Continuous delivery 9 hours
a, DiffucapsW 30:70 8 hours
SODASW (Spheroidal Oral
Drug Absorption System)








50:50 Not stated: two distinct
peaks approximately
4 hours apart
Wax matrix Continuous release 8 hours
ait, Lebanon, Malaysia, Oman, Philippines, Qatar, Saudi Arabia, Singapore,
any, Greece, Iceland, Ireland, Latvia, Lichtenstein, Lithuania, Luxembourg, Malta,
Switzerland, UK.
temala, Honduras, Jamaica, Mexico, Trinidad and Tobago, USA.
Peru, Uruguay, Venezuela.
itzerland, UK.
Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal,
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therefore, achieve similar efficacy at a lower total daily dose
than the racemic MPH formulations [8]. MedikinetW re-
tard (MEDICE Pharma GmbH and co. KG, Iserlohn,
Germany) also provides 50% of the racemic MPH dose
immediately, using a 50:50 mixture of immediate release
and enteric-coated beads to delay MPH delivery [9].
BiphentinW (Purdue Pharma, Pickering, Ontario, Canada)
uses a multilayer-release bead formulation to provide a
rapid initial release of 40% of the total racemic MPH
dose followed by delivery of the remaining MPH
from a controlled-release core [10]. Equasym XLW
(Metadate CDW; Shire Pharmaceuticals Ireland Ltd,
Dublin, Ireland) employs the DiffucapsW bead delivery
technology to deliver 30% of the racemic MPH imme-
diately and 70% from extended-release beads, while
ConcertaW (Janssen-Cilag Ltd, High Wycombe, UK)
uses the osmotic controlled-release delivery system
(OROSW) to release 22% of racemic MPH immediately
followed by gradual delivery of the remaining MPH
throughout the day [11,12]. Continuous delivery of ra-
cemic MPH is provided by DaytranaW (Noven Pharma-
ceuticals Inc., Miami, Florida, USA) via the MPH
transdermal system, a diffusion-based patch applied to
the skin [13].
The differing time–action profiles provided by these
long-acting MPH formulations may allow clinicians to
target specific periods of the day that are particularly
relevant for a patient, facilitating individualization of
ADHD treatment.
Response to MPH in the treatment of ADHD varies
between patients. While MPH is effective in the majority
of children in the short term, there is significant variation
in individual response to treatment, with a minority not
achieving adequate symptom control and others unable to
tolerate MPH due to adverse effects [14-16]. Optimization
of dose and treatment regimen is needed, therefore,
and continued monitoring of response throughout the
treatment period is required [16]. Given the range of
MPH formulations available and the individualization
of therapy that is required to ensure optimal treatment,
direct head-to-head studies of long-acting MPH formula-
tions can provide important information about the com-
parative pharmacokinetics (PK), pharmacodynamics and
efficacy of the different formulations. While a number
of studies compare long- and short-acting MPH formu-
lations, for example MedikinetW retard versus twice-
daily immediate-release MPH [17], few direct head-to
-head studies of two or more long-acting MPH formula-
tions have been performed to date.
The objective of this review was to bring together the
evidence available from head-to-head studies of long-acting
MPH formulations and provide evidence-based clinical
guidance on treatment selection.Methods
A literature search was conducted using the MEDLINE
(1950–Present) and PsycINFO (1806–Present) databases
to identify head-to-head studies of long-acting MPH
formulations. The final search was conducted on 21 March
2012 and followed the PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) guidelines for
methodology. The following search terms were developed,
refined and tested for relevance by cross-checking results
against a list of known relevant articles: MeSH terms:
attention deficit disorder with hyperactivity/drug therapy;
methylphenidate/therapeutic use; All Fields: Concerta;
Ritalin LA; OROS and ADHD; Medikinet; Equasym XL
and ADHD; long-acting methylphenidate; Diffucaps
and ADHD; SODAS and methylphenidate. In addition,
searches for Biphentin and ADHD, methylphenidate
transdermal system and ADHD, and Metadate CD and
ADHD were performed following the final search to
corroborate findings (no additional studies were identified
that met the search criteria). No filters were used during
the search as key references were missed during the devel-
opment and testing of the search strategy when filters were
applied. No language, publication date or publication status
limitations were imposed. All search results were combined
into a single master database and duplicates removed.
References within the master database were then screened
by title for the following keywords to identify articles
of possible relevance: methylphenidate; Concerta; Ritalin
LA; OROS; Medikinet; Equasym XL; Diffucaps; SODAS;
Spheroidal Oral Drug Absorption System; extended-release;
extended release; long-acting; long acting; modified-release;
modified release; single-dose; single dose; once-daily;
once daily; methylphenidate transdermal system; MTS;
osmotic-release; osmotic release; laboratory; meta-analysis;
once-a-day; once a day. Articles were selected if the title in-
dicated a comparison of two or more long-acting methyl-
phenidate preparations in humans; articles with ambiguous
titles were selected for further screening by abstract and/or
full text. Studies involving subjects of any age with ADHD
of any subtype receiving long-acting MPH were considered.
Study diagnostic criteria and inclusion criteria were not
assessed during the screening process. Both switching
studies and observational studies were included; however,
non-systematic review articles and non-peer-reviewed
data were not included in this review. Articles selected by
title screening were then assessed independently for eligibil-
ity by a second person; potentially eligible articles were then
screened by abstract and disagreement regarding eligibility
was resolved through discussion. If the suitability of an art-
icle was unclear, the full-text article was assessed. Reference
lists of relevant systematic reviews and meta-analyses were
cross-referenced against identified articles. Data extraction,
performed independently by two people, included article
category, drug and dosing, age group, sample size, diagnosis,
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measures, main findings and conclusions. Possible sources
of bias were identified as multiple reports from single stud-
ies and variability in outcome measures and parameters
among studies. Meta-analysis was not feasible owing to the
heterogeneity in outcomes reported across all study types
included in the review; however, a systematic approach was
applied to identify comparisons of interest and synthesize
the findings of multiple studies.
Results and discussion
The master database included 15,295 references, which
were screened by title for relevant articles (Figure 1). Of
these, 287 articles were screened by abstract and 33 arti-
cles were identified for inclusion in the review. One
additional article, which was not in the master database
(Silva et al., 2008 [18]), was identified from the reference list
of a systematic review (Brams et al., 2010 [19]). Publications
included in the review are summarized in Table 2 and
comprised nine articles from PK studies (nine studies); nine
articles from laboratory school studies (six studies); two
articles from randomized controlled trials (RCTs; two
studies); three articles from switching studies (two studies)Records identified through
database searching
(n=15,295)
Records screened by title
(n=15,295)












Articles included in review
(n=34)
Figure 1 Flow diagram of screened and included articles.and three articles from one observational study. As the
studies were diverse and the reported outcomes were
heterogeneous, consistent comparisons of interest could
not be made across all study types. For PK articles (n = 9),
comparisons of interest were bioequivalence of long-
acting MPH formulations to ConcertaW, overall MPH
exposure, time to peak plasma MPH concentration,
plasma MPH concentrations across the day, and the effect
of long-acting MPH formulations on dopamine transport
occupancy. Comparisons of interest for laboratory school
study articles (n = 9) were efficacy of long-acting MPH
formulations across the day, and the effect of symptom
severity and gender on MPH response. For RCTs,
switching and observational study articles, similarities
and differences between outcomes relating to different
long-acting MPH formulations are reported, as available.
An overview of the main conclusions from eight system-
atic reviews and meta-analyses addressing long-acting
ADHD medications, including MPH, are also presented.
Effect sizes were reported in only five articles from two
studies (excluding meta-analyses); therefore, effect sizes
are presented in the text where appropriate but are not




xt articles excluded (n=25)
ot a comparison of 2 or more long-acting
PH formulations (n=21)
on-systematic review (n=4)
Table 2 Summary of articles identified in the literature search that compare ≥2 long-acting MPH formulations








ConcertaW (18, 36, 54 mg) n = 36 Not applicable Not stated PK parameters for 24 hours post-dose,
including bioequivalence
Equasym XLW (20, 40, 60 mg) 21–40 years
Haessler et al.,
2008 [26]
Ritalin LAW (40 mg) n = 28 Not applicable Not stated PK parameters for 24 hours post-dose,
including bioequivalence
MedikinetW retard (40 mg) 18–30 years
Markowitz et al.,
2003 [22]
ConcertaW (18 mg) n = 20 Not applicable Not stated PK parameters for 24 hours post-dose,
including bioequivalence
Ritalin LAW (20 mg) 21–34 years
Modi et al.,
2000 [23]
ConcertaW (18 mg) n = 36 Not applicable Not stated PK parameters for 30 hours post-dose
Ritalin SRW (20 mg) 18–41 years
Pierce et al.,
2010 [24]
ConcertaW (18, 27, 36, 54 mg) n = 71 ADHD according to DSM-IV-TR criteria Possibly ODD PK properties of d,l-MPH after single,
multiple, fixed and escalating doses
of ConcertaW and DaytranaWDaytrana





ConcertaW (18 mg) n = 24 Not applicable Not stated PK parameters for 24 hours post-dose,
including bioequivalence
BiphentinW (20 mg) 19–25 years
Schutz et al.,
2009 [28]
Equasym XLW (20 mg) n = 14 Not applicable Not stated PK parameters for 24 hours post-dose,
including bioequivalence
MedikinetW retard (20 mg) 22–43 years
Spencer et al.,
2010 [21]
ConcertaW (36 mg) n = 21 Not applicable Not stated PET imaging
Equasym XLW (40 mg) 18–55 years
Tuerck et al.,
2007 [27]
Focalin XRW (20 mg) n = 25 Not applicable Not stated PK parameters for 24 hours post-dose,
including bioequivalence




ConcertaW (18, 36 mg) n = 36 ADHD according to C-DISC criteria Not stated SKAMP-Attention; SKAMP-Deportment;
SKAMP-Combined; Math-Attempted;
Math-CorrectRitalin LA
W (20 mg) 6–12 years
Muniz et al.,
2008 [33]
ConcertaW (36, 54 mg) n = 84 Combined-type ADHD (89%);
Inattentive-type ADHD (11%) according
to DSM-IV criteria, established by C-DISC
Not stated SKAMP-Combined; SKAMP-Attention;
SKAMP-Deportment; Math-Attempted;
Math-Correct; CPRSFocalin XR
W (20, 30 mg) 6–12 years
Schulz et al.,
2010 [38]
Ritalin LAW (20 mg) n = 147 Combined-type ADHD (55%);
Inattentive-type ADHD (37%);
Hyperactive/impulsive-type ADHD
according to DSM-IV criteria, confirmed
by K-SADS
Disturbance in social behaviour
(n = 4), initial insomnia (n = 2),
ODD (n = 2), dysphemia (n = 1),
encopresis (n = 1)
SKAMP-Combined; Math-Attempted;
Math-Correct; NCBRF-TIQ

















Table 2 Summary of articles identified in the literature search that compare ≥2 long-acting MPH formulations (Continued)
Silva et al.,
2005 [32]
ConcertaW (18 mg) n = 54 Combined inattentive/hyperactive-type
ADHD (70%); Inattentive-type ADHD
(28%); Hyperactive/impulsive-type
ADHD (2%) according to DSM-IV criteria
Not stated SKAMP-Attempted; SKAMP-Deportment;
SKAMP-Combined; Math-Attempted;
Math-CorrectRitalin LA
W (20 mg) 6–12 years
Silva et al.,
2008 [18]
ConcertaW (36, 54 mg)




Inattentive-type (6%) according to
DSM-IV criteria




et al., 2004 [34]
ConcertaW (18, 36, 54 mg)





according to DSM-IV criteria and
confirmed by DISC
Comorbid condition (25%),





et al., 2007 [35]
ConcertaW (18, 36, 54 mg)














et al., 2008 [36]
ConcertaW (18, 36, 54 mg) n = 184 Combined-type (82%); Inattentive-type
(13%); Hyperactive/impulsive-type (5%)
according to DSM-IV criteria, confirmed
by DISC
Comorbid condition (25%),
including anxiety and ODD
GMM analysis





ConcertaW (18, 36, 54 mg) n = 184 Combined-type (82%); Inattentive-type
(13%); Hyperactive/impulsive-type (5%)
according to DSM-IV criteria, confirmed
by DISC
Comorbid condition (25%),
including anxiety and ODD
SKAMP-Attention; SKAMP-Deportment;
PERMP





ConcertaW (18, 36 mg) n = 113 Combined-type ADHD according to
DSM-IV, confirmed by interview
(DCL-ADHD)
ODD or conduct disorder
(36%)
SKAMP-D; DAYAS; FBB-ADHD
MedikinetW retard (10, 20, 30 mg) 6–16 years
Findling et al.,
2008 [43]
ConcertaW (18, 27, 36, 54 mg) n = 282 Combined-type ADHD (71–86%);
Inattentive-type ADHD (11–26%);
Hyperactive/impulsive-type ADHD
(1–2%) according to DSM-IV-TR criteria
Possibly ODD ADHD-RS-IV mean total score; CTRS-R;
CPRS-R; CGI–S; CGI–I; PGA; MPH plasma
concentrations at 7.5, 9 and 10 hours
post-dose




ConcertaW (18, 27, 36, 45, 54 mg) n = 171 Combined-type ADHD (77%);
Inattentive-type ADHD (21%);
Hyperactive/impulsive -type ADHD
(2%) according to DSM-IV-TR criteria
Possibly ODD ADHD-RS-IV mean total scores; CGI–I;
PGA, CPRS-R; CGI–S
Ritalin LAW (10, 20, 30, 40, 50 mg) 6–12 years
Equasym XLW (10, 15, 20, 30, 40, 50 mg)

















Table 2 Summary of articles identified in the literature search that compare ≥2 long-acting MPH formulations (Continued)
Bukstein et al.,
2009 [47]
ConcertaW (18, 27, 36, 45, 54 mg) n = 171 See Arnold et al., 2010 [46] Possibly ODD AIM-C; MSS
Ritalin LAW (10, 20, 30, 40, 50 mg) 6–12 years
Equasym XLW (10, 15, 20, 30, 40, 50 mg)
DaytranaW (10, 15, 20, 30 mg)
Dirksen et al.,
2002 [48]
Equasym XLW (20, 40, 60 mg) n = 308 ADHD according to DSM-IV criteria
(diagnostic code 314.01)
Not stated CGI–I; CGI–S; CGI-Efficacy Index
ConcertaW (18, 36, 54, 72 mg) 6–17 years
Other long-acting MPH (excluding




Equasym XLW (10–120 mg) n = 822 Disturbance of activity/attention (F90.0;
55%); hyperkinetic conduct disorder
(F90.1; 36%); other hyperkinetic disorders
(F90.8; 8%) according to ICD-10 criteria
Not stated CGI–S; CGI–I; FBB-ADHD; DAYAS; SDQ-P







Equasym XLW (10–120 mg) n = 782 For total study sample (n = 822) see
Doepfner et al., 2011 [49]
Not stated FBB-ADHD; CGI–S; DAYAS; KINDL
Other long-acting MPH





et al., 2011 [51]
See Doepfner et al., 2011 [49] n = 822
6–17 years






Equasym XLW; Ritalin LAW; n = 29 articles Effect size expressed as SMD




Equasym XLW; Ritalin LAW; n = 23 articles Effect size expressed as SMD












et al., 2006 [52]
ConcertaW; Ritalin LAW; Equasym
XLW; MedikinetW retard





















XRW; Equasym XLW; Ritalin LAW
n = 18 articles SKAMP, CADS-T, IOWA Conners’ Rating






Equasym XLW; Ritalin LAW





ConcertaW; Equasym XLW; Ritalin LAW Not stated SKAMP, 10-Minute Math Test, PK
measures, effect size
ADHD, attention deficit hyperactivity disorder; ADHD-RS-IV, ADHD Rating Scale-version IV; AIM-C, ADHD Impact Module-Children; C-DISC, Diagnostic Interview Schedule for Children 1997; CADS-T, Conners’ ADHD/
DSM-IV Scale for teachers; CGI–I, Clinical Global Impressions–Improvement; CGI–S, Clinical Global Impressions–Severity of Illness; CGIS-T, Conners’ Global Index Scale for teachers; CPRS, Conners’ Parent Rating Scale;
CTRS-R, Conner’s Teacher Rating Scale-Revised; DAYAS, Day Profile of ADHD Symptoms; DCL, Diagnostic Checklist for ADHD; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition; DSM-IV-TR,
Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition, Text Revision; FBB-ADHD, Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit–Hyperaktivitätsstörung (German symptom checklist for attention
deficit hyperactivity disorder); GMM, Growth Mixture Modelling; ICD-10, International Classification of Diseases, version 10; KINDL, Kinder Lebensqualitatsfragebogen; IOWA, Inattention/Overactivity With Aggression;
K-SADS, Kiddie Schedule for Affective Disorders and Schizophrenia; MPH, methylphenidate; MSS, Medication Satisfaction Survey; NCBRF-TIQ, Nisonger Child Behaviour Rating Form; ODD, oppositional defiant
disorder; PERMP, permanent product measure of performance; PET, Positron Emission Tomography; PGA, Parent Global Assessment; PK, pharmacokinetic; SAMS; Satisfaction with Medication Scale; SD, Standard
deviation; SDQ-P, Strengths and Difficulties Questionnaire for Parents; SKAMP, Swanson, Kotkin, Agler, M-Flynn and Pelham Rating Scale; SKAMP-D, German version of Swanson, Kotkin, Agler, M-Flynn and Pelham
Rating Scale; SMD, Standard Mean Difference.

















Coghill et al. BMC Psychiatry 2013, 13:237 Page 9 of 24
http://www.biomedcentral.com/1471-244X/13/237PK studies
In total, nine studies investigated the PK properties of
long-acting MPH formulations in head-to-head compari-
sons. Six studies used ConcertaW as a comparator; of these,
two studies compared ConcertaW with Equasym XLW
[20,21], while four individual studies compared
ConcertaW with Ritalin LAW [22], Ritalin SRW [23],
DaytranaW [24] and BiphentinW [25]. Therefore, this
provides head-to-head comparisons of ConcertaW with
five long-acting MPH formulations. Additional com-
parisons of long-acting MPH formulations were Ritalin
LAW versus MedikinetW retard [26], Ritalin LAW versus
Focalin XRW [27], and Equasym XLW versus
MedikinetW retard [28]. All, apart from one of these
studies, were performed in adults. The ConcertaW ver-
sus DaytranaW study was performed in children and
adolescents [24].
Head-to-head PK studies of ConcertaW versus Equasym XLW,
Ritalin LAW, Ritalin SRW, DaytranaW and BiphentinW
Bioequivalence to ConcertaW and overall MPH exposure
Three studies assessed the bioequivalence of long-acting
MPH formulations with ConcertaW [20,22,25]. In each,
bioequivalence was considered present if the 90% confi-
dence interval (CI) ratio of the two MPH formulations
under comparison was within 80–125%. ConcertaW was
not bioequivalent to comparable daily doses of Equasym
XLW (maximum concentration [Cmax]−1; area under the
curve [AUC]0–4; AUC0–6) or Ritalin LA
W (AUC0–∞) [20,22].
While ConcertaW and BiphentinW were bioequivalent
according to AUC0–t (90% CI 105.62–116.41) and AUC0–∞
(90% CI 106.25–116.33), they were, however, not bio-
equivalent according to Cmax (90% CI 113.85–130.39)
[25]. Bioequivalence between ConcertaW and Ritalin
SRW or DaytranaW was not evaluated [23,24].
While ConcertaW (18 mg) had similar overall (24 hour)
MPH exposure (AUC) to Equasym XLW (20 mg) and
Ritalin LAW (20 mg) [20,22], exposure to MPH over
24 hours was significantly higher for BiphentinW (20 mg)
compared with ConcertaW (18 mg, p = 0.002) [25]. This
was due to a concentration–time profile for BiphentinW
that resulted in the delivery of a significantly greater pro-
portion of MPH compared with ConcertaW in the first
4 hours post-dose followed by comparable levels of MPH
later in the day [25]. Systemic exposure to d-MPH during
treatment with DaytranaW was higher in children than ado-
lescents [24]. Systemic exposure to d-MPH from a single
dose of DaytranaW (10 mg/9 hours) was similar to that from
a single dose of ConcertaW (18 mg) in children, but only
60–80% of that of ConcertaW (18 mg) in adolescents [24].
This difference in systemic exposure was attributed to the
lower body weight in children compared with adolescents
[24]. After multiple escalating doses of DaytranaW in chil-
dren (final dose of 30 mg/9 hours), systemic exposure to d-MPH was 1.4-fold to 1.6-fold higher compared with mul-
tiple escalating doses of ConcertaW (final dose: 54 mg) [24].
The investigators concluded that higher accumulation of d-
MPH with DaytranaW compared with ConcertaW was a
result of continued long-term administration rather than
frequency of dosing or changes in clearance, and also that
changes in skin permeability resulting from application-
site erythema may be a cause of increased absorption of
MPH from DaytranaW during multiple dosing [24]. In
contrast with the findings in children, systemic exposure
to d-MPH was similar in adolescents for both DaytranaW
and ConcertaW [24].
Time to peak plasma MPH concentration (Tmax) In
head-to-head studies of ConcertaW with five long-acting
MPH formulations, ConcertaW generally reached peak
plasma MPH concentration later (5–8 hours post-dose) than
the other long-acting MPH formulations investigated (Rit-
alin LAW, BiphentinW, Ritalin SRW and Equasym XLW; 4–
6 hours post-dose) with the exception of DaytranaW which
reached peak levels 10 hours post-dose (Table 3) [20,22-25].
Tmax was not provided by Gonzalez et al. for Equasym XL
W
versus ConcertaW and therefore could not be included
in Table 3; however, both MPH formulations displayed
biphasic characteristics, providing a sharp initial increase in
MPH plasma concentration at approximately 1 hour post-
dose and a second peak 6 hours post-dose (Equasym
XLW) and 6–8 hours post-dose (ConcertaW) [20].
Plasma MPH concentrations across the day Morning: In
the first 4 hours post-dose, Equasym XLW (20, 40, 60 mg),
Ritalin LAW (20 mg), Ritalin SRW (20 mg) and BiphentinW
(20 mg) reached higher plasma MPH concentrations
(AUC0–4 and Cmax0–4) than comparable daily doses of
ConcertaW (Table 3) [20,23-25]. Data for AUC0–4 and
Cmax0–4 for Concerta
W versus DaytranaW were not
presented by Pierce and colleagues; however, a delay of ap-
proximately 2 hours in the absorption of d-MPH in chil-
dren and adolescents following a single dose of DaytranaW
(10 mg/9 hours) was reported, which was not apparent in
those receiving ConcertaW, or following multiple fixed or
escalating doses of DaytranaW [24].
Afternoon and evening: While Equasym XLW (20, 40,
60 mg) produced greater MPH concentrations compared
with the nearest daily dose of ConcertaW (18, 36, 54 mg) up
to 6 hours post-dose, this reversed later in the day, with
ConcertaW sustaining greater plasma MPH concentrations
than Equasym XLW at 8, 10 and 12 hours post-dose [20]. A
similar pattern of MPH concentrations was observed with
Ritalin LAW (20 mg), which had higher peak MPH concen-
trations than ConcertaW (18 mg) over the first 8 hours
post-dose, followed by similar concentrations at 10 hours
and lower concentrations at 12 hours post-dose [22]. The
biphasic PK profile of Ritalin LAW resulted in a trough in
Table 3 Pharmacokinetic parameters across the day for head-to-head pharmacokinetic studies (presented for
single-dose comparison only)
Cmax, ng/mL Tmax, hours AUC, ng • h/mL
Cmax0–4 Cmax4–10 Cmax Tmax0–4 Tmax4–10 Tmax AUC0–4 AUC4–10 AUC0–∞
Gonzalez et al., 2002 [20] (fasted state)
ConcertaW – – – – – – 6.28 – 36.43
(18 mg) (2.65) (13.50)
Equasym XLW – – – – – – 10.01 – 39.74
(20 mg) (3.06) (11.75)
ConcertaW – – – – – – 11.88 – 94.05
(36 mg) (5.86) (44.51)
Equasym XLW – – – – – – 20.36 – 98.49
(2 × 20 mg) (8.74) (52.05)
ConcertaW – – – – – – 18.81 – 143.38
(54 mg) (7.18) (64.83)
Equasym XLW – – – – – – 32.01 – 145.34
(3 × 20 mg) (13.09) (65.21)
Haessler et al., 2008 [26] (fed state)
Ritalin LAW 11.8 12.8 13.3 – – – 33.5 57.8 126.8
(40 mg) (3.95) (4.13) (4.04) (11.07) (16.91) (34.5)
MedikinetW retard 16.5 18.3 19.6 – – – 42.4 68.0 141.5
(40 mg) (6.69) (5.66) (5.95) (16.54) (19.47) (38.3)
Haessler et al., 2008 [26] (fasted state)
Ritalin LAW 10.0 14.5 14.5 – – – 27.6 57.1 114.1
(40 mg) (3.51) (3.02) (3.02) (8.89) (14.36) (30.8)
MedikinetW retard 16.5 14.7 17.1 – – – 44.9 49.3 115.7
(40 mg) (4.62) (4.45) (4.88) (14.77) (18.47) (37.2)
Markowitz et al., 2003 [22] (fasted state)
ConcertaW 3.4 – 5.9 3.3 – 6.0 9.3 – 66.9
(18 mg) (44)a (37)a (36)a (28)a (51)a (49)a
Ritalin LAW 7.0 – 9.9 2.1 – 5.5 18.5 – 78.7
(20 mg) (47)a (41)a (48)a (15)a (44)a (54)a
Modi et al., 2000 [23] (fasted state)
ConcertaW – – 3.75 – – 6.7 – – 42.0
(18 mg) (1.0) (1.8) (14)
Ritalin SRW – – 4.84 – – 3.7 – – 46.7
(20 mg) (1.6) (1.6) (16)
Pierce et al., 2010 [24] (fasted state; age 6–12 years)
ConcertaW – – 7.80 – – 6.02 – – 94.2
(18 mg) (3.35) (4.0–10.0)b (43.8)
DaytranaW – – 9.30 – – 10.0 – – 99.2
(10 mg/9 hours) (3.60) (8.0–12.0)b (42.9)
Pierce et al., 2010 [24] (fasted state; age 13–17 years)
ConcertaW – – 4.95 – – 8.0 – – 60.1
(18 mg) (1.42) (1.0–10.0)b (16.3)
DaytranaW – – 4.15 – – 10.0 – – 48.7
(10 mg/9 hours) (2.59) (6.0–12.0)b (21.9)
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Table 3 Pharmacokinetic parameters across the day for head-to-head pharmacokinetic studies (presented for
single-dose comparison only) (Continued)
Reiz et al., 2008 [25] (fed state)
ConcertaW 3.33 4.09 4.13 2.51 5.86 4.96 8.77 26.29 48.21
(18 mg) (1.03) (1.01)c (1.01) (1.15) (1.61)c (2.56) (3.37) (5.57)c (9.79)
BiphentinW 4.8 4.73 5.07 2.26 6.02 3.71 12.35 28.57 54.01
(20 mg) (1.39) (1.09)c (1.32) (0.64) (1.26)c (2.03) (3.78) (6.68)c (13.11)
Schutz et al., 2009 [28] (fed state)
Equasym XLW 3.82 – 4.05 3.24 – 3.99 9.66 – 37.35
(20 mg) (0.96) (0.96) (1.13) (1.88) (3.24) (10.92)
MedikinetW retard 4.83 – 5.26 2.82 – 4.06 11.72 – 39.90
(20 mg) (1.87) (2.11) (1.00) (1.65) (4.64) (13.77)
Tuerck et al., 2007 [27] (fasted state)
Focalin XRW 13.7 14.9 15.5 1.5 6.5 5.8 36.3 59.1 119
(20 mg) (4.6) (4.0) (4.3) (1.0–2.0)b (4.5–7.0)b (1.0–7.0)b (10.6) (16.0) (40.7)
Ritalin LAW 13.2 16.3 16.4 2.0 6.5 6.5 35.0 60.9 122
(40 mg) (3.0) (4.5) (4.4) (1.5–4.5)b (4.0–8.0)b (2.0–7.0)b (8.7) (15.0) (36.3)
Data are shown as mean (standard deviation) unless stated otherwise.
AUC, area under the curve; Cmax, maximum plasma methylphenidate concentration; Tmax, time to maximum plasma methylphenidate concentration.
aPercentage coefficient of variation; bmedian (range); c4–12 hours post-dose.
N.B. Spencer et al., 2010 [21] did not present the values listed; therefore this reference was not included in the table.
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dose, which may coincide with a typical lunchtime school
break [22]. Following a rapid increase in plasma MPH con-
centration with a mean peak concentration at 3.7 hours for
Ritalin SRW (20 mg; Table 3), plasma MPH concentration
declined rapidly compared with ConcertaW (18 mg), which
had a higher plasma MPH concentration at 8, 10 and
12 hours post-dose [23].
Although AUC4–12 and Cmax4–12 were significantly higher
for BiphentinW (20 mg) compared with ConcertaW (18 mg,
p = 0.037 and p = 0.002, respectively; Table 3), plasma MPH
concentrations for the two formulations were not signifi-
cantly different at 8–12 hours post-dose (AUC8–12),
suggesting the potential for similar efficacy between the
two formulations in the evening [25]. For the period cover-
ing the school day (AUC0–8), plasma MPH concentration
for BiphentinW (20 mg) was 128.4% that of ConcertaW
(18 mg) [25]. The investigators noted that if switching a
patient from ConcertaW to BiphentinW, it may be appropri-
ate to initiate treatment with BiphentinW at a lower daily
dose than that of previously received ConcertaW; how-
ever, if switching a patient from BiphentinW to
ConcertaW, the closest marketed dose could be used [25].
As mentioned above, DaytranaW was the only long-acting
MPH formulation to reach peak plasma MPH concentra-
tion later than ConcertaW in head-to-head studies [24].
Cmax, reached at 10 hours post-dose in a single-dose com-
parison, was greater in children receiving DaytranaW
(10 mg/9 hours) compared with those receiving ConcertaW
(18 mg), and higher in children than adolescents for bothMPH formulations (Table 3). This pattern was also ob-
served following multiple fixed doses for 7 days and
multiple escalating doses over 28 days [24].
Head-to-head PK study of Medikinet
W retard versus Ritalin LAW
In a head-to-head comparison of MedikinetW retard
(40 mg) and Ritalin LAW (40 mg), food intake was shown
to affect the bioavailability of MedikinetW retard but
not that of Ritalin LAW [26]. Under fasted conditions,
MedikinetW retard showed a steady absorption profile with
a single Tmax in healthy adult volunteers; however, under
fed conditions, a biphasic kinetic profile more closely
resembling a twice-daily dosing regimen was observed.
Food intake also affected overall exposure to MPH
(AUC0–∞), which was lower in the fasted than in the fed
state (Table 3). In contrast, Ritalin LAW (40 mg) had a bi-
phasic kinetic profile under both fasted and fed conditions
[26]. Ritalin LAW and MedikinetW retard were bioequiva-
lent in the fasted state but not in the fed state (when a bi-
phasic kinetic profile was observed for both formulations),
during which Cmax for Ritalin LA
W was lower compared
with that of MedikinetW retard [26]. Haessler and col-
leagues suggested that, as regular breakfast intake is often
challenging in children with ADHD, the unaffected bio-
availability with regard to food intake may be a potential
advantage of Ritalin LAW over MedikinetW retard [26].
Head-to-head PK study of MedikinetW retard versus Equasym XLW
In a head-to-head comparison of MedikinetW retard
(20 mg) and Equasym XLW (20 mg), taken as
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XLW before breakfast), the two MPH formulations were not
bioequivalent in the first 4 hours post-dose (AUC0–4) [28].
MedikinetW retard had a slightly higher and slightly earlier
peak MPH plasma concentration (mean [standard deviation]
4.83 [1.87] ng/mL at 2.82 [1.00] hours post-dose) compared
with Equasym XLW (3.82 [0.96] ng/mL at 3.24 [1.13] hours
post-dose; Table 3) [28]. Bioequivalence was demonstrated
4–24 hours post-dose (AUC4–t; 90% CI 88.6–103.1), how-
ever [28]. While a significant gender x treatment interaction
(p = 0.018) for maximum plasma MPH concentration from
4 hours to last observation (Cmax4–t) was noted, no
other significant gender effects were observed for other
PK parameters [28].
Head-to-head PK study of Focalin XRW versus Ritalin LAW
Focalin XRW (20 mg), a long-acting formulation containing
pure d-MPH, and a 40 mg daily dose of the long-acting
racemic MPH formulation, Ritalin LAW, were bioequivalent
and had very similar plasma MPH concentration profiles
over the course of the study [27]. No gender effects on
body-weight-adjusted AUC values were reported [27].
Effects of MPH formulation on dopamine transport occupancy
Spencer et al. employed positron emission topography to
investigate dopamine transporter (DAT) occupancy in the
brain 10 hours after dosing with ConcertaW (36 mg)
and Equasym XLW (40 mg) in 21 healthy adults [21].
Plasma d-MPH concentration was also determined 9, 10
and 11 hours post-dose to enable a comparison between
peripheral PK and central brain effects. ConcertaW
resulted in greater plasma d-MPH concentrations and
greater brain effects (DAT occupancy) at 10 hours com-
pared with a similar daily dose of Equasym XLW,
suggesting that both peripheral and brain PK profiles can
be predicted based on the MPH delivery profile of the
long-acting MPH formulation. Plasma concentration
was a predictor of DAT occupancy for both MPH for-
mulations, but the correlation between plasma DAT occu-
pancy and d-MPH concentration was stronger with
Equasym XLW compared with ConcertaW. While the rea-
sons for this were unclear, the authors noted that this may
be associated with a more rapid rate of change in plasma
MPH concentration following dosing with Equasym XLW,
owing to the greater immediate-release component of this
MPH formulation compared with ConcertaW [21].
Adverse events Overall, adverse events associated with
long-acting MPH formulations were similar and consistent
with the known pharmacological effects of MPH, most
commonly including loss of appetite, insomnia, nausea,
dizziness, headache and tachycardia [20,23-25,27,28].
Unfortunately, the available data do not permit us to
address questions about clinically relevant adverse eventsspecific to different MPH preparations; for example, are
the lower peak plasma MPH concentrations observed with
long-acting MPH formulations compared with immediate-
release formulations associated with lower levels of adverse
events, such as appetite loss or increases in blood pressure
and pulse rate? Does the absence of a drop in plasma MPH
concentration observed towards the end of the 4-hour
dosing period for immediate-release MPH result in more
consistent appetite suppression? Furthermore, and most
pertinent to this review, do the different PK profiles of the
long-acting MPH formulations result in different adverse
event profiles in certain patients? Reviews of the adverse
effects of medication for ADHD, including MPH, can be
found elsewhere [29,30].
Laboratory school studies
Of 34 publications, nine head-to-head comparisons of
long-acting MPH formulations were laboratory school
studies; eight of which employed ConcertaW as a compara-
tor. Two studies each compared ConcertaW with Ritalin
LAW [31,32] and Focalin XRW [18,33], while ConcertaW was
compared with Equasym XLW in four publications derived
from one study (the COMACS Study) [34-37]. A single
study compared Ritalin LAW with MedikinetW retard [38].
With increasing treatment of school-aged children with
stimulant and non-stimulant medications for ADHD, it is
important to examine the efficacy and safety of such
therapies across the day in an educational setting as
well as at home. The laboratory school methodology
employs a standardized, regular and repeated cycle of
classroom and less-structured activities, representing
those encountered in a typical school day, to assess both
academic performance and child behaviour in a controlled
environment [39]. Regular collection of safety measures
also allows the observation of adverse treatment effects in
patients with ADHD in a simulated educational setting
[39]. Pharmacodynamic data (behaviour and performance)
in laboratory school studies are typically collected using the
Swanson, Kotkin, Atkins, M-Flynn, Pelham (SKAMP) scale;
a questionnaire completed by trained observers at regular
intervals [40]. The SKAMP scale comprises six deportment
items (interacting with other children, interacting with
adults, remaining quiet, staying seated, complying with the
teacher’s requests or directions, and following the rules)
and seven attention items (getting started on assignments,
sticking with tasks, sticking with activities, completing
assigned work, performing work accurately, and being neat
and tidy while writing or drawing) [40]. An objective meas-
ure of academic productivity is provided by a 10-minute
written math test administered during the classroom period
(consistently used across studies but variably referred to as
permanent product or PERMP), from which the number of
math test problems attempted (Math-Attempted) and the
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Figure 2 Comparative efficacy of ConcertaW and Equasym XLW
versus placebo over time in a laboratory school study. Data
represent all dose levels combined (Equasym XLW 20, 40, 60 mg;
ConcertaW 18, 36, 54 mg). Corresponding effect sizes for each
timepoint are shown in the table. Originally published in Swanson
JM, et al. Pediatrics 2004, 113:e206-e216. Reproduced with permission
from Pediatrics, Vol. 113, Page(s) e206–e216, Copyright ©2004 by the
AAP. *Equasym XLW was significantly better than ConcertaW;
†ConcertaW was significantly better than Equasym XLW; ‡placebo was
significantly better than both Equasym XLW and ConcertaW. MCD,
Equasym XLW; PERMP, permanent product measure of performance;
PLA, placebo; SEM, standard error of the mean; SKAMP, Swanson,
Kotkin, Atkins, M-Flynn, Pelham rating scale.
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tests scores are used as surrogate measures of treatment
efficacy. While the main purpose of laboratory school
studies is to assess treatment effects in an educational
setting, the protocol can be extended into the evening
(up to 12 hours post-dose) to assess whether the observed
effects extend beyond the traditional school day.
Head-to-head laboratory school studies of ConcertaW
versus Equasym XLW, Ritalin LAW and Focalin XRW
Efficacy of long-acting MPH formulations across the
day Morning: Equasym XLW and Ritalin LAW provided su-
perior symptom control to comparable daily doses of
ConcertaW in the morning [31,37]. The COMACS Study
evaluated differences in the efficacy of bioequivalent doses
of Equasym XLW and ConcertaW using the laboratory
school protocol [37]. Equasym XLW (20, 40, 60 mg) was
superior to comparable daily doses of ConcertaW (18,
36, 54 mg) for SKAMP-Attention, SKAMP-Deportment
and correct math test scores at 1.5–4.5 hours post-dose
[37] (Figure 2). Effect sizes for overall, combined dose levels
for each formulation, shown in Figure 2, were greatest for
Equasym XLW at 3 hours post-dose (SKAMP-Attention
0.72 versus 0.48 for ConcertaW; SKAMP-Deportment 0.89
versus 0.50 for ConcertaW). In a post-hoc analysis of the
COMACS Study, it was predicted that lower doses of
Equasym XLW (20, 40 mg) would provide similar levels of
symptom control to 36 and 54 mg doses of ConcertaW, re-
spectively, in the morning [34]. This hypothesis was based
on the similar immediate-release components of the two
formulations at the stated, respective, doses. While
Equasym XLW 20 mg was associated with a stronger effect
and more rapid onset of action than ConcertaW (36 mg)
at 1.5 hours post-dose, there was no significant overall
difference in placebo-adjusted SKAMP scores between
the two formulations at 3, 4.5 or 6 hours post-dose and
no significant difference in placebo-adjusted SKAMP
scores was observed between Equasym XLW 40 mg and
ConcertaW 54 mg from 1.5 to 6.0 hours post-dose [34].
Two laboratory school studies examined the comparative
efficacy of ConcertaW and Ritalin LAW [31,32]. Lopez
and colleagues compared ConcertaW (18 mg) and Ritalin
LAW (20 mg) [31]. In line with observations from PK stud-
ies [22], they observed that, in the first 4 hours post-
dose, Ritalin LAW (20 mg) resulted in significantly greater
improvements from baseline than ConcertaW (18 mg) in
SKAMP-Attention (p = 0.015) (Figure 3), SKAMP-
Deportment (p < 0.001), SKAMP-Combined (p < 0.001) and
correct math test scores (p = 0.026) [31]. In contrast, Silva
and colleagues demonstrated equivalent efficacy for Ritalin
LAW (20 mg) and ConcertaW (18 mg) during the first
4 hours (and 8 hours) post-dose for SKAMP-Attention,
SKAMP-Deportment and math test scores [32]. It is
possible that the findings of Silva and colleagues,however, may be a consequence of including a clinically
more heterogeneous study population than the Lopez
et al. study. In the study by Silva et al., 64% of subjects had
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Figure 3 Comparative efficacy of ConcertaW (18, 36 mg) and
Ritalin LAW (20 mg) versus placebo in a laboratory school
study. Figure shows change from pre-dose baseline in SKAMP-
Attention score over time. In the first 4 hours post-dose, Ritalin LAW
(20 mg) resulted in significantly greater improvements from baseline
than ConcertaW (18 mg) in SKAMP-Attention (p = 0.015). Originally
published by Springer and Adis Data Information BV/Paediatr Drugs,
volume 5, 2003, 545–555, Comparative efficacy of two once daily
methylphenidate formulations (Ritalin LA and Concerta) and placebo
in children with attention deficit hyperactivity disorder across the
school day, Lopez F, et al., Figure 3, ©Adis Data Information BV 2003;
with kind permission from Springer Science + Business Media B.V.
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Figure 4 Comparative efficacy of ConcertaW (d,l-MPH-ER; 36,
54 mg) and Focalin XRW (d-MPH-ER; 20, 30 mg) versus placebo over
time in a laboratory school study. SKAMP, Swanson, Kotkin, Atkins, M-
Flynn, Pelham rating scale. Error bars: standard deviation. Reprinted/
Reproduced from Silva R, et al. Psychopharmacol Bull 2008, 41:19–33, with
permission from MedWorks Media Global, LLC.
Coghill et al. BMC Psychiatry 2013, 13:237 Page 14 of 24
http://www.biomedcentral.com/1471-244X/13/237been receiving a stable dose of 40 mg/day MPH prior to
enrolment compared with all subjects stabilized to 20 mg/
day MPH in the Lopez et al. study. This may have resulted
in a suboptimal response in the Silva et al. study [31,32].
Ritalin LAW (20 and 40 mg) also demonstrated super-
ior symptom control compared with the 36 mg dose of
ConcertaW in the first 4 hours post-dose [31,32]. Lopez
and colleagues demonstrated a significantly greater mean
change from baseline in SKAMP-Attention (p = 0.043),
SKAMP-Deportment (p = 0.004) and SKAMP-Combined
(p = 0.003) scores for Ritalin LAW (20 mg) compared
with ConcertaW (36 mg) in the first 4 hours post-dose
[31] (Figure 3). While Silva et al. also demonstrated signifi-
cant improvements in SKAMP-Attention (p = 0.022) and
Math-Correct (p = 0.033) scores for this dose comparison
and time period, Ritalin LAW (20 mg) and ConcertaW
(36 mg) were equivalent in SKAMP-Deportment and
Math-Attempted scores [32]. For all efficacy measures, im-
provements from baseline were significantly greater with
Ritalin LAW (40 mg) than with ConcertaW 36 mg over
the first 4 hours post-dose, evident within 1 hour of
dosing and persisting until 8 hours of evaluation [32].
Focalin XRW was superior to higher daily doses of
ConcertaW (20 versus 36 mg, and 30 versus 54 mg,
respectively) at 0.5–6 hours post-dose [18,33]. Two
head-to-head laboratory school comparisons of Focalin
XRW with higher daily doses of ConcertaW (20 versus
36 mg, and 30 versus 54 mg, respectively) demon-
strated that Focalin XRW had an earlier onset of effi-
cacy compared with ConcertaW, with significantly greaterimprovements from baseline in SKAMP-Combined,
SKAMP-Attention, SKAMP-Deportment scores and math
test scores with Focalin XRW than with ConcertaW at time
points between 0.5 and 6 hours post-dose [18,33] (Figure 4).
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showed trends nearing statistical significance in favour of
Focalin XRW over ConcertaW (Focalin XRW 20 mg versus
ConcertaW 36 mg, p = 0.074; Focalin XRW 30 mg versus
ConcertaW 54 mg, p = 0.068) [33]. Significantly greater im-
provements from baseline with Focalin XRW compared
with ConcertaW were also observed in Math-Attempted
and Math-Correct scores at 3 hours (20 versus 36 mg)
and 4–5 hours (30 versus 54 mg) post-dose [18,33].
Afternoon and evening: While the COMACS Study
demonstrated the superior efficacy of Equasym XLW
compared with ConcertaW in the morning, similar effi-
cacy of comparable daily doses of the two MPH formu-
lations was observed at 6.0–7.5 hours post-dose, and
ConcertaW demonstrated superiority over comparable
doses of Equasym XLW at 12 hours post-dose [37]
(Figure 2). In cross-dose comparisons, lower doses of
ConcertaW (18 and 36 mg) provided equivalent symptom
control to higher doses of Equasym XLW (40 and 60 mg,
respectively) at 7.5 hours and 12 hours post-dose [34]. In
a reversed-dose comparison, a lower dose of Equasym
XLW (20 mg) was comparable at 7.5 hours post-dose with
a higher dose of ConcertaW (36 mg) but ConcertaW
(36 mg) was superior to Equasym XLW (20 mg) at 12 hours
post-dose [34]. However, when Equasym XLW (40 mg)
was compared with ConcertaW (54 mg) in a similar cross-
dose comparison, ConcertaW was superior to Equasym
XLW at both 7.5 and 12 hours post-dose [34].
Over the 8-hour classroom period employed by Lopez
et al., Ritalin LAW (20 mg) resulted in a significantly
greater mean change from baseline (AUC0–8) compared
with ConcertaW (18 mg) in SKAMP-Combined (p =
0.010) and SKAMP-Deportment (p = 0.018) scores and
demonstrated trends towards significance in SKAMP-
Attention (p = 0.074) [31]. Ritalin LAW (20 mg) also
demonstrated trends towards superiority over a higher
daily dose of ConcertaW (36 mg) in SKAMP-Combined
(p = 0.061) and SKAMP-Deportment (p = 0.078) scores
over the 8-hour assessment period [31]. Silva and col-
leagues aimed to replicate and extend the findings of
Lopez et al. using a similar study design but a longer,
12-hour classroom protocol. However, in contrast with
Lopez et al., Silva and colleagues demonstrated com-
parable efficacy of Ritalin LAW (20 mg) and ConcertaW
(18 mg) over the first 8 hours post-dose (AUC0–8), possibly,
as stated earlier, owing to a clinically more heterogeneous
study population [32]. Using the extended 12-hour class-
room protocol, Silva et al. observed significantly greater
changes from baseline at 8–12 hours post-dose (AUC8–12)
in SKAMP-Combined and SKAMP-Deportment scores
with ConcertaW 18 and 36 mg compared with Ritalin LAW
20 mg (but not 40 mg), and significantly more correct math
test responses with ConcertaW 36 mg than with Ritalin
LAW 20 mg (p = 0.046) were observed [32].While post-hoc analyses of AUC0–6 for SKAMP-
Combined scores showed trends, nearing statistical
significance, favouring Focalin XRW (20 and 30 mg)
over higher daily doses of ConcertaW (36 and 54 mg), dif-
ferences between the two MPH formulations from 6 to
12 hours post-dose (AUC6–12) failed to reach significance
(20 versus 36 mg, p = 0.244; 30 versus 54 mg, p = 0.594)
[33]. Although ConcertaW and Focalin XRW demon-
strated similar efficacy at 7–9 hours post-dose [18],
ConcertaW demonstrated significantly greater improve-
ments in SKAMP-Combined, SKAMP-Attention and
SKAMP-Deportment scores at 10–12 hours post-dose
compared with lower daily doses of Focalin XRW (36 ver-
sus 20 mg, and 54 versus 30 mg, respectively) [18,33].
Both laboratory school studies comparing ConcertaW
with Focalin XRW employed the Conners’ Parent Rating
Scale (CPRS) to obtain additional parental ratings of their
child’s behaviour during the previous week. Muniz and col-
leagues demonstrated that, while Focalin XRW (20 mg) had
a significantly greater effect on parent-rated symptom con-
trol than ConcertaW (36 mg), no significant differences be-
tween the change in CPRS scores for Focalin XRW 30 mg
and ConcertaW 54 mg were observed [33]. In contrast, Silva
et al. found no significant difference for change from base-
line in CPRS scores, between formulations for the lower
dose comparison (Focalin XRW 20 mg versus ConcertaW
36 mg) and found ConcertaW (54 mg) to be superior to
Focalin XRW (30 mg); however, no explanation is pro-
vided for this disparity between study findings [18].
Head-to-head laboratory school study of Ritalin LAW versus
MedikinetW retard
One laboratory school study compared Ritalin LAW
(20 mg) with MedikinetW retard (20 mg) using a 7.5 hour
laboratory school protocol and found no clinically relevant
differences between the two MPH formulations [38] (Fig-
ure 5). Both treatment groups demonstrated comparable
improvements in SKAMP-Combined score and math
test scores until peak efficacy was reached at 3 hours post-
dose [38]. Change from screening visit in Nisonger Child
Behaviour Rating Form score (a parent-rated assessment of
child and adolescent behaviour) demonstrated that both
Ritalin LAW and MedikinetW retard improved disruptive be-
haviours [38].
Effect of symptom severity on treatment choice
A secondary analysis of the COMACS Study using growth
mixture modelling analysis (a statistical technique to identify
subgroups within a population with different trajectories of
change over time) of total SKAMP scores investigated the
effect of symptom severity on MPH response to Equasym
XLW and ConcertaW [36]. Results suggested heterogeneity in
pharmacodynamic response to MPH by children with


























Figure 5 Comparative efficacy of Ritalin LAW (20 mg) and
MedikinetW retard (20 mg) versus placebo in a laboratory
school study. Figure shows SKAMP-Combined score over the first
4.5 hours post-dose. ‘Clinical relevance’ lines outline the predefined non-
inferiority margin. SKAMP, Swanson, Kotkin, Atkins, M-Flynn, Pelham
rating scale. Originally published in Schulz E et al. J Child Adolesc
Psychopharmacol 2010, 20:377–385. Reproduced with permission. The
publisher for this copyrighted material is MaryAnn Liebert, Inc. publishers.
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with increasing severity of ADHD symptoms, the larger
immediate-release bolus of Equasym XLW provided greater
symptom control in the morning compared with near-
equal and bioequivalent doses of ConcertaW (effect size
0.59 and 0.77 at 1.5 and 3 hours post-dose, respectively, in
children with high symptom severity; effect size 0.58, 0.60
and 0.54 at 1.5, 3 and 4.5 hours post-dose, respectively, in
children with intermediate symptom severity) [36]. The
efficacy of ConcertaW was unaffected by symptom severity,
thus the difference between the pharmacodynamic profiles
of the two MPH formulations became more evident as
symptom severity increased. The predicted superiority of
ConcertaW at 12 hours post-dose was observed only in chil-
dren with intermediate symptom severity (effect size 0.37).
It must be noted that these findings may not translate dir-
ectly into clinical practice, however, as the subgroups of
symptom severity were identified according to performance
in the placebo condition in the laboratory classroom setting
and not on the basis of parent or teacher ratings in the
home or school environment [36].
Effect of gender on response to MPH
A significant effect of gender on response to MPH was ob-
served in a further secondary analysis of the COMACS
Study [35]. This was independent of MPH formulation
(ConcertaW or Equasym XLW), however. Females dem-
onstrated a superior response to MPH, measured using
SKAMP-Combined scores (controlled for placebo and
baseline scores, and for the presence of comorbid anxiety)
when compared with males at 1.5 and 3 hours post-dose, an
equivalent response to males between 4.5 and 6 hours post-
dose and a greater decline in response compared with males
between 7.5 and 12 hours post-dose [35]. Analyses usingPERMP scores confirmed this faster decline in response to
MPH in females compared with males [35]. The response of
female patients to MPH may, therefore, require additional
assessments later in the day to determine the optimal dose
of MPH [35]. Unfortunately, as most studies include only
small numbers of females, the power of other head-to-head
studies to investigate the effect of gender in MPH response
is limited. While a significant gender by treatment inter-
action (p = 0.018) for maximum plasma MPH concentration
from 4 hours to last observation (Cmax4–t) was noted in a
head-to-head PK study of Equasym XLW and MedikinetW
retard performed in healthy adults, no other significant
gender effects were observed [28]. In addition, no gender
effects were noted in a head-to-head PK study of Focalin
XRW and Ritalin LAW [27].
General observations and adverse events from laboratory
school studies
An important general observation from the laboratory
school studies comparing Equasym XLW and ConcertaW
is that superiority at any point in time was achieved by
the formulation with the highest expected plasma MPH
concentration (predicted from PK data available) [37,42].
Despite dose selection based on clinical titration, the size of
the drug effect obtained in the early morning appears to be
directly related to the absolute dose delivered by the
immediate-release MPH bolus of each formulation [37,42].
The duration of action of clinical effects is also in line
with what would be predicted from PK data. Adverse events
for all of the oral long-acting MPH formulations were gener-
ally mild to moderate in severity and commonly included
abdominal pain, headache and decreased appetite
[18,31-33,37,38]. While adverse events were generally similar
between different formulations, in one study treatment-
related abdominal pain and anorexia were more frequent in
subjects receiving MedikinetW retard (5/147; 3.4% and 6/
147; 4.1%, respectively) than those receiving Ritalin LAW (1/
147; 0.7% and 3/147; 2.0%, respectively) [38]. This difference
in frequency was not assessed for significance and the inves-
tigators concluded that there were no relevant differences
between MedikinetW retard and Ritalin LAW regarding the
profile, frequency or intensity of adverse events [38].
Head-to-head RCTs of long-acting MPH formulations
To date, only two head-to-head non-laboratory school
RCTs have been performed, both of which included
ConcertaW as a comparator.
ConcertaW versus DaytranaW
In a Phase III, double-blind, double-dummy, parallel-group,
placebo-controlled, naturalistic home and school trial,
children (n = 282) were randomized to receive either
ConcertaW, DaytranaW or placebo [43]. Following a 5-
week dose optimization period, children who reached
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a 2-week dose-maintenance phase during which assess-
ment of treatment efficacy and safety were performed at
the end of each week. Blood samples were collected from
participants at 7.5, 9 and 10.5 hours post-dose during one
of the last three study visits for determination of plasma
MPH concentration. By the end of the dose optimization
period, the majority of children were receiving
ConcertaW at a dose of 36 mg (32.4%) or 54 mg (44.1%)
or DaytranaW at 20 mg/9 hours (34.2%) or 30 mg/9 hours
(36.8%). Results at study endpoint revealed no signifi-
cant differences between ConcertaW and DaytranaW for:
mean change from baseline in ADHD Rating Scale-version
IV (ADHD-RS-IV) scores (the primary efficacy measure of
the study); mean change from baseline in Conner’s Teacher
Rating Scale-Revised (CTRS-R) total score; or mean change
from baseline in CPRS-R total score in the morning or the
afternoon. Furthermore, the majority of children receiving
DaytranaW (71.9%; n = 69) and ConcertaW (66.3%; n = 59)
were rated as improved using the Clinical Global Impres-
sions–Improvement (CGI–I) scale at study endpoint, while
69.8% (n = 67) and 60.7% (n = 54), respectively, were rated
as improved using the Parent Global Assessment (PGA)
scale.
Higher plasma concentrations of d-MPH and l-MPH
were observed after 9 hours of treatment with
DaytranaW compared with 9 hours post-dosing with
ConcertaW, indicating that greater systemic exposure to
MPH is observed in the latter part of the day with
DaytranaW.
ConcertaW versus MedikinetW retard
A randomized, double-blind, cross-over study design
was used to investigate the efficacy of ConcertaW and
MedikinetW retard with equivalent daily doses (but different
immediate-release components) and different daily doses
(but similar immediate-release components) in the school
and home environment [42]. Efficacy was rated by teachers
using the German version of the SKAMP scale (SKAMP-
D), while both teachers and parents rated ADHD symp-
toms using the Day Profile of ADHD Symptoms
(DAYAS) [42].
MedikinetW retard with a higher immediate-release
component and similar daily dose to ConcertaW was su-
perior to ConcertaW (20 versus 18 mg and 30 versus
36 mg, respectively) in the first 3 hours of school and 4–
6 hours into the school day, as assessed using SKAMP-
D [42]. MedikinetW retard with a similar immediate-
release component to ConcertaW in the morning but
with a lower daily dose was non-inferior to ConcertaW
(10 versus 18 mg and 20 versus 36 mg, respectively) in
the first 3 hours and 4–6 hours of the school day
(SKAMP-D) [42]. No evidence for the superiority of
ConcertaW over MedikinetW retard with equivalent dailydoses in the late afternoon and evening was observed
using DAYAS teacher or parent ratings [42].
Adverse events No significant difference in the frequency
of adverse events was observed between ConcertaW and
DaytranaW; the majority of adverse events were mild to
moderate in severity [43]. Application-site reactions were
noted as being among adverse events resulting in study
discontinuation for patients receiving DaytranaW. While
mild erythema was common, 77% of subjects reported ei-
ther no or minimal evidence of irritation. A higher inci-
dence of tic disorders was observed in patients receiving
DaytranaW (n = 7, 7.1%; nine events) compared with
ConcertaW (n = 1, 1.1%; one event); however, this was
deemed unlikely to reflect a greater risk of tics associ-
ated with DaytranaW [43-45]. The most frequent adverse
events noted in RCTs were headache, abdominal pain, de-
creased appetite, nausea, vomiting and insomnia [42,43]. In
addition, there was no evidence of differences in overall tol-
erance (assessed by the investigator, parents and teachers)
between ConcertaW and MedikinetW retard [42].
Switching and observational studies
Of 34 publications included in the review, three publica-
tions derived from two open-label switching studies [46-48]
and three publications derived from one observational
study [49-51] were identified. All studies included
ConcertaW as a comparator.
Switching studies
In one switching study, children aged 6–12 years with ADHD
on a stable dose of oral long-acting MPH (ConcertaW,
Equasym XLW or Ritalin LAW), not exceeding 54 mg/day,
underwent abrupt switching to DaytranaW using a pre-
defined dose-transition schedule. Titration was based on
changes in ADHD-RS-IV score and Clinical Global Impres-
sions–Severity (CGI–S) scale score. Measures of ADHD
symptoms and quality of life were obtained using ADHD-
RS-IV, CPRS-R, CGI–S, CGI–I, PGA and the ADHD
Impact Module-Child (AIM-C) [46,47].
Abrupt conversion from oral long-acting MPH for-
mulations to an optimum dose of DaytranaW using a
dose-transition schedule was not associated with de-
terioration of symptom control [46,47]. After 1 week of
treatment with DaytranaW, the majority of children (78%)
had a CGI–I score indicating improvement or no change
and mean ADHD-RS-IV total score was similar to that
at baseline, indicating little change in ADHD symptoms
when subjects switched to DaytranaW from oral long-acting
MPH formulations [46]. After 4 weeks of treatment with
DaytranaW, 96% of children had CGI–I scores rated as ‘im-
provement or no change’ relative to baseline. Furthermore,
a significant improvement from baseline was observed
in ADHD-RS-IV mean total score (p < 0.0001). Forty-two
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during the study, most of which were dose increases
(38% of subjects) [46]. Optimal nominal doses of
DaytranaW, which ranged from 10 mg/9 hours (n = 23) to
30 mg/9 hours (n = 59) were below the nominal doses of
oral long-acting MPH from which subjects were switched.
Clinicians could consider initiating treatment with
DaytranaW at a smaller patch size than the oral dose re-
ceived previously. However, treatment for each patient
should be optimized on an individual basis [46,47].
Improvements from baseline in behaviour (PGA, CPRS-R),
health-related quality of life (HRQoL; AIM-C) for both
the child and the family, compliance and economic impact
(number of missed school days; hours of tutoring, nursing,
home healthcare and use of other services required;
number of work days missed by parent/caregiver) were
also observed after treatment for 4 weeks with DaytranaW
[47]. Differences between subgroups were noted: greater
improvements from baseline to endpoint in child HRQoL
were reported for: children switching from Ritalin LAW;
children aged 6–9 years; and females rather than males
[47]. In addition, greater improvement in the AIM-C
School/Missed-Doses Worry Scale was observed in sub-
jects who switched to DaytranaW from Equasym XLW
than in those who switched from ConcertaW or Ritalin
LAW [47]. For all prior-treatment groups, caregiver satisfac-
tion with DaytranaW treatment was high and 82.6% of care-
givers reported improvements in their child’s social
interactions since switching to DaytranaW [47]. According
to the authors, the apparent superiority of DaytranaW ob-
served during the study, however, is more likely to be due
to careful titration and clinical monitoring for the study
duration rather than to the product itself [46,47].
In a second switching study, 308 children with ADHD
who were either untreated or currently receiving treatment
with MPH (immediate-release MPH, extended-release
MPH excluding ConcertaW, or ConcertaW) were switched
to Equasym XLW for 3 weeks [48]. Children currently re-
ceiving MPH started Equasym XLW at a dosage based on
clinical judgement and the patient’s current MPH dose,
while previously untreated children started Equasym XLW
treatment at a dose of 20 mg. Equasym XLW was titrated
for all patients on a weekly basis according to clinical judge-
ment. Measures of ADHD symptom control and thera-
peutic response were obtained at weeks 1, 2 and 3 using
CGI–I and the CGI–Efficacy Index and compared with
baseline scores. Of those who were previously receiving
ADHD medication (181; 59%), most switched from
ConcertaW (41.4%) or immediate-release MPH (36.5%) with
only 9% switching from a long-acting MPH other than
ConcertaW. Overall, 60.6% of children switching from a
previous MPH formulation were responders to Equasym
XLW (CGI–I score of 1 [very much improved] or 2
[much improved]) at week 3 and approximately half(55%) of children switching from ConcertaW demon-
strated improvement from baseline in CGI–I at week 3.
The majority of children (63%) switching from a previ-
ous MPH treatment also demonstrated a moderate or
marked therapeutic effect with either no or minimal side-
effects, as measured using the CGI–Efficacy Index. The au-
thors suggested that improvements observed in patients
previously receiving MPH may be due to treatment
optimization and differences in PK between the two MPH
formulations.
Adverse events Consistent with commonly reported ad-
verse events associated with MPH, 59.6% of caregivers
agreed that DaytranaW decreased their child’s appetite
and 34.8% agreed that treatment with DaytranaW made
it more difficult for their child to fall asleep at night
[47]. Such late-day side effects may be attenuated by
early removal of the patch [44]. Adverse events with
DaytranaW and Equasym XLW were mostly mild to mod-
erate in severity and most commonly included headache,
decreased appetite, insomnia and abdominal pain [48].
Despite a transdermal route of administration,
DaytranaW was associated with those adverse events typ-
ically observed with oral long-acting MPH, with the added
issue of application-site reactions that included normal ap-
pearance at the patch site with moderate itching, as well as
erythema with severe itching. However, most subjects
reported no or mild discomfort [46,47]. One subject
reported two serious adverse events (acute depression and
suicide attempt) while receiving 30 mg DaytranaW for
16 days that were considered possibly related to treatment.
Observational study
The OBSEER study was a non-interventional, non-
controlled, observational study. Patients with ADHD
intended for treatment with Equasym XLW, either previ-
ously treatment-naive, receiving treatment with other MPH
formulations (immediate-release or long-acting, most
commonly immediate-release MedikinetW and MedikinetW
retard, respectively), receiving a different pharmacological
therapy or receiving non-pharmacological therapy were
observed for 6–12 weeks in routine care. As this was a
non-interventional study, treatment optimization was not
part of the study remit and MPH dose adjustments were
at the discretion of the treating physician. Measures of
ADHD symptoms and quality of life were obtained using
the CGI–S scale, the German ADHD symptom checklist
(Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit–
Hyperaktivitätsstörung [FBB-ADHD]; rated by teachers
and parents), DAYAS (rated by teachers and parents) and a
HRQoL questionnaire (Kinder Lebensqualitätsfragebogen
[KINDL]) [49]. Despite most children (69.8%) previously
receiving MPH medication, improvement in ADHD symp-
toms was observed following the switch to Equasym XLW
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toms (CGI–S) was observed in the treatment-naive sub-
group (Cohen’s d = 1.73); however, a reduction in CGI–S
was also observed in patients previously receiving a long-
acting MPH formulation (Cohen’s d = 0.76) [50].
The reduction in parent-rated ADHD symptoms
(Cohen’s d = 0.79; FBB-ADHD) was larger than the reduc-
tion in teacher-rated ADHD symptoms (Cohen’s d = 0.41;
FBB-ADHD) [50]. For parent-rated DAYAS scores, the
largest reduction in ADHD and oppositional defiant
disorder symptoms in patients previously receiving a long-
acting MPH formulation was observed in the early after-
noon (Cohen’s d = 0.63), with smaller but still substantial
improvements observed in the morning before school, late
afternoon and evening (Cohen’s d range 0.44–0.49). No
significant difference was observed between prior treat-
ment subgroups in the evening [50]. Less improvement
was noted in teacher-rated DAYAS scores for the first
2–3 hours and second 2–3 hours of the school morning
(Cohen’s d = 0.14 and 0.39, respectively) compared with
parent-rated DAYAS scores for the morning before school
(Cohen’s d = 0.49), afternoon until 4 pm (Cohen’s d = 0.63),
late afternoon until 7 pm (Cohen’s d = 0.45) and evening
(Cohen’s d = 0.44) [50]. While parents and physicians were
not blinded to study treatment or dose, teachers were not
formally notified of the change in treatment. The lower
effect sizes in the teacher ratings may be a more accurate
representation of treatment effect, therefore, as they were
not influenced by expectation and dissatisfaction with prior
treatment [49].
Improvement following the initiation of treatment with
Equasym XLW was also observed in mean KINDL score
and KINDL scales for self-esteem, friends and school
(parent and patient ratings) and family (patient ratings).
The largest effect size in patients formerly receiving
long-acting MPH in parent-rated quality of life was on
the KINDL friends scale (Cohen’s d = 0.42), while the
largest effect size noted for patient-rated quality of life
was on the KINDL family scale (Cohen’s d = 0.37) [50,51].
Overall, adherence during Equasym XLW treatment was
frequently rated as superior to adherence during prior
treatment; however, 12.8% of patients previously receiving
long-acting MPH had better adherence to prior treatment,
compared with 8.0% for all treatments overall [51].
Adverse events The most frequent adverse events
recorded during the OBSEER study were psychiatric dis-
orders (19.8% of all patients), metabolism and nutrition
disorders (2.4%), and gastrointestinal disorders (2.2%),
with tics being the most frequent single adverse event
recorded (106 events in 100/822 [12.2%] patients). While
the frequency of tics was high, the authors noted that
conclusions regarding the emergence of treatment-related
tics were limited as patients with pre-existing tics werenot excluded from the study and emergent tics were not
differentiated from those pre-existing. Serious adverse
events (n = 38) were recorded for 21/822 (2.5%) patients,
which the investigators noted was high compared with
previous studies. The investigators proposed that this may
be due to various factors, including the long duration of
observation in the OBSEER study, a lack of data regarding
whether the adverse events were present under the previ-
ous medication, missing data for 10.7% of patients and
possible incorrect categorization of adverse event serious-
ness by the investigators.
Meta-analyses and systematic reviews
Eight systematic reviews and meta-analyses addressed
long-acting ADHD medications, including, but not limited
to, MPH for the treatment of ADHD. An overview of the
main conclusions of these reviews is presented.
Consideration of the onset and duration of efficacy of
long-acting MPH formulations in the context of the pa-
tient’s individual needs when selecting an appropriate
formulation was highlighted [19,52,53]. The pattern of
efficacy generally follows that predicted by the PK profile
of the MPH formulation [53]. As such, efficacy offset
varies between long-acting MPH formulations, although
whether this is clinically perceptible outside the research
setting is unknown [19,53]. Greater efficacy during the
first 8 hours post-dose compared with later in the day may
be beneficial for parents/caregivers during the pre-school
period (getting the child ready for school and travelling to
school) and during the school day; however, some families
may prefer greater symptom control in the evenings to
improve concentration for homework completion, or for
greater behavioural control in social/familial interactions
[19,53]. Selection of the optimal MPH formulation may
be influenced by the individual’s sensitivity to appetite
problems and insomnia; therefore, MPH formulations
with shorter duration of action may be more appropriate
over longer-acting formulations to reduce interference with
dinnertime and sleep [52,54].
With regard to administration of medication, Equasym
XLW, MedkinetW retard and Ritalin LAW capsules can
be opened and sprinkled on food, which may have a
compliance benefit over ConcertaW in patients who
have difficulty swallowing. However, surreptitious admin-
istration of medication by parents/caregivers should
not be undertaken as this may result in a lack of trust
between the patient and parent/caregiver [52].
The importance of head-to-head studies for the direct
comparison of the efficacy of different medications was
highlighted but the lack of uniformity in study design
parameters used to assess medication efficacy, particu-
larly for studies assessing long-acting stimulants was
noted as a significant limitation with current studies
[55-57].
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with ADHD, Peterson et al. found that short-acting stimu-
lants were more effective than long-acting stimulants in
the treatment of adults with ADHD [58]. While an initial
analysis by Faraone et al. supported this finding, no signifi-
cant difference between the effect sizes for long- and short-
acting stimulants in the treatment of adults with ADHD
was detected after study confounders and publication
bias were accounted for [57]. Furthermore, differences
in study methodology (inclusion/exclusion criteria, outcome
measures analysed and literature search timing) were also
suggested to contribute to the contradiction in findings from
the two meta-analyses [57].
Conclusions
The objective of this review was to bring together the
evidence available from head-to-head studies of long-acting
MPH formulations and to increase understanding of their
basic properties, discuss similarities and differences, and
provide information that can guide treatment selection.
In addition to supporting the conclusions of existing
meta-analyses and systematic reviews on long-acting
MPH formulations, our review of head-to-head studies
reinforces the finding that, at a group level, the pattern
of efficacy across the day generally follows that predicted
by the PK profile of the formulation. The timecourse of
both plasma MPH concentration and central brain effects
(DAT occupancy) may be predicted based on the MPH
delivery profile of a long-acting formulation [21]. It must
be noted, however, that there is significant variability in
PK profiles across the day at an individual level and that,
as a consequence of this, the individual response to any
given product and dosing strategy may vary substantially.
The clinical consequences of this variability are that no one
treatment is superior for all patients and that individualized
treatment optimization is an important clinical task. To
make the best use of the various long-acting MPH prepara-
tions clinicians need to understand the similarities and dif-
ferences between them and how to harness these to achieve
the best results for their patients.
For patients achieving significant but suboptimal effects
with a long-acting MPH medication, switching to another
MPH formulation should be considered. This advice re-
lates to situations in which there has been at least a partial
response to MPH (e.g., adequate symptom coverage for a
certain period of the day) and the clinician is trying to fine
tune and optimize treatment. Such an approach may
prove beneficial and can often be undertaken without loss
of symptom control during the period of transition from
one formulation to another. As noted previously, responses
to formulations may vary between individuals and the
time–action profile of the medication should be considered
during switching and tailored to the patient’s needs. The
availability of the different long-acting MPH formulationsvaries across the world, and even within continents, and
clearly impacts on the options available to the clinician. At
the present time the greatest range is available to patients
in the USA (Table 1). In cases where a lower daily dose of
MPH is preferred, data have shown that children and
adolescents could be treated with a lower daily dose of
MedikinetW retard and DaytranaW than ConcertaW without
clinically relevant deterioration in symptom control during
school time [42,47,50]. However, it is also acceptable to
increase the daily dose of MPH in order to achieve opti-
mal symptom control [52] and indeed higher daily doses
should not necessarily be seen as negative [59]. Clinicians
are often uncertain about correct dosing when switching
patients from immediate- or extended-release MPH to a
long-acting MPH formulation with an immediate-release
component of <50% (ConcertaW in particular). As a conse-
quence, many patients receive suboptimal treatment. It is
usually appropriate to use the immediate-release compo-
nent of each formulation as the reference and try to adjust
for this when switching between MPH formulations. A
limitation of current studies is that they have mostly
focused on the total daily dose rather than equivalent
immediate-release components. Data from head-to-head
studies of long-acting MPH formulations suggest that,
across formulations, equivalent immediate-release compo-
nents provide similar symptom control in the morning and
this would be our clinical suggestion. As an example, if one
wants to switch a patient from 20 mg of MedikinetW retard
(50:50 immediate- and extended-release) to ConcertaW
(22:78 immediate- and extended-release) to try to alle-
viate breakthrough symptoms at the end of the school
day, then 45 mg of ConcertaW would give the equiva-
lent immediate-release dose. Although the supporting
data are not reviewed here, when there is little clinical re-
sponse to MPH at the end of a careful titration, switching
from MPH to another stimulant or a non-stimulant medi-
cation is likely to be the most beneficial for such patients
who are poor responders to MPH.
Duration of required symptom control may vary between
individuals. Although it has been argued that an ascending
PK profile is required to combat acute tolerance [60] it is
likely that for some individuals, reaching a peak plasma
MPH concentration at a minimum of 6–8 hours post-dose,
as observed for ConcertaW and DaytranaW, may be quite
late in the day as the school/work morning is over and
symptom control may not be optimal when required. In
such cases clinicians may favour one of the 8-hour formula-
tions. However, there is also evidence that for many pa-
tients, ADHD symptoms continue into the late afternoon
and evening [61]. Where this is the case, extending symp-
tom control beyond 8 hours has the potential to benefit
many, if not most, patients with ADHD. This may be par-
ticularly important for adults and adolescents, who are
often required to maintain high levels of functioning over
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allow for flexibility in duration of symptom control, which
can be tailored to the individual patient’s needs. Twelve-
hour symptom coverage can be obtained using a formula-
tion such as ConcertaW on its own, or by combining one
of the 8-hour preparations with an additional immediate-
release dose at around 4 pm. Female patients have been
shown to have a faster decline in response to MPH
compared with males [35] and may require closer as-
sessments of their afternoon symptom control to de-
termine optimal MPH dose.
Flexibility in how the medication can be taken may be
of particular benefit for some patients. For example, the
ability to open capsules and sprinkle the medication on
food may be of benefit for patients who have difficulty
taking tablets and offers an advantage for pre-school
children who are not yet able to swallow pills. If regularly
eating breakfast is a challenge for the patient, a formulation
for which bioavailability is not affected by food intake may
be preferred. In such cases, Ritalin LAW may have a poten-
tial advantage over MedikinetW retard [26]. Alternatively, a
transdermal rather than an oral mode of action may be pre-
ferred by some patients. While the side-effect profiles are
similar between different long-acting MPH formulations,
DaytranaWmay be associated with application-site reactions.
This review has highlighted several unmet needs.
While we recognize that the evidence to date suggests
that the profile of clinical action across the day can gener-
ally be predicted from the PK profile of a particular prep-
aration, the direct evidence to support this proposition is
almost all from head-to-head studies that compared
ConcertaW with one other long-acting MPH formulation.
The laboratory school protocol seems to be the ideal
methodology for addressing outstanding questions; how-
ever, at the time of writing, only one laboratory school
study had been performed in which ConcertaW was not
the comparator. This study compared equivalent daily
doses of Ritalin LAW and MedikinetW retard, both of
which have a 50/50 immediate-release/extended-release
delivery profile, and showed no clinically relevant differ-
ences between the two formulations [38]. We therefore
believe that more head-to-head laboratory school studies
of alternative combinations of long-acting formulations
are required to provide evidence-based guidance on treat-
ment selection and guide the development of clinical guide-
lines, and to inform the decisions of regulators and those
making decisions about reimbursement and ultimately the
decisions made in day-to-day clinical practice. In particular,
further studies comparing the efficacy of formulations
containing racemic d,l-MPH with d-MPH (Focalin XRW)
would be of particular interest. Pragmatic head-to-head
studies looking at dose optimization across the day in the
short- and long-term, and longer-term comparative studies
to assess efficacy and safety over time, are also required aswell as laboratory school studies comparing MPH with
other ADHD medications.
In addition to these studies, which would be applicable to
all ages, further studies using an age-appropriate laboratory
school-style protocol in adults are needed to assess real-life
medication effects across the day. More studies of the
effects of long-acting MPH formulations in pre-school chil-
dren, both within age-appropriate laboratory school settings
and assessing their impact in more naturalistic settings on
developmental and academic outcomes would also be of
interest. Further research into the effect of comorbidities
and symptom severity as modifiers of treatment response
with the various long-acting MPH formulations available
is also necessary. Compliance and adherence may differ
between different long-acting medications; however, it is
unknown whether this is a true reflection of medication
adherence or an effect of study involvement. More studies
investigating the impact of the different formulations and
related dosing strategies on adherence could throw light
on these questions.
This review has a number of potential limitations. While
two extensive databases were searched to identify relevant
articles for inclusion in the review, the authors are aware of
studies that were not retrieved by the search terms. These
include an open-label study of 447 children and adolescents
switching from immediate-release MPH, extended-release
MPH, or no treatment, to MedikinetW retard [62]. Sig-
nificant improvements from baseline at 4–6 weeks were
observed in ADHD symptom severity, as evaluated by phy-
sicians and parents, in patients switching from ConcertaW
(n = 64) but not in those switching from Ritalin SRW/Ritalin
LAW (n = 26). The superior efficacy of MedikinetW re-
tard compared with ConcertaW is probably due to the
larger immediate-release bolus from MedikinetW retard
(50%, versus 22% for ConcertaW), while the lack of sig-
nificant improvement with MedikinetW retard com-
pared with Ritalin SRW/Ritalin LAW may be explained by
the motivation of patients to participate in the study, and
not necessarily because the prior therapy was suboptimal.
The diversity of head-to-head studies of long-acting
MPH formulations and their reported outcomes creates
a challenge when drawing general conclusions and provid-
ing clinical recommendations. Emerging studies provide
important data on the comparative efficacy of formula-
tions available, but further studies are necessary to provide
more evidence-based guidance for clinical practice. Effect
sizes have been cited in the review where appropriate;
however, heterogeneity in study design and reported out-
comes precluded the undertaking of meta-analysis.
Despite these limitations there are several clear mes-
sages for clinicians using long-acting MPH preparations
to treat patients with ADHD. Different patients have
both different treatment needs and responses to MPH.
There is now clear evidence that, in order to optimize
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to treatment is required. This involves both an initial ti-
tration onto medication and a continued follow up, with
careful adjustments in dose and often in MPH formula-
tion. It is important to track symptoms and response
across the day. One possible tool for this is the Dundee
Difficult Times of the Day Scale (D Coghill, personal
communication, available from [63]). It is clear from this
review that no one long-acting MPH preparation is
clearly superior to another. However, even though
some of the formulations are very similar to each other,
each has its own particular profile and there are differ-
ences with respect to mode of delivery, PK/pharmaco-
dynamic profile, dosing, duration of action, interaction
with food and adverse effects. In addition to carefully
collecting information about ADHD symptoms and the
way that they change across the day, clinicians need to be
aware of the, often subtle, differences between formulations
when trying to optimize treatment for their individual pa-
tients. A reasonable starting position is to titrate to an ad-
equate morning response, as for many patients this will be
followed by good symptom control across the rest of the
day. If not, further adjustments in dose, a change of MPH
formulation or change to a different class of drug may be
required. Such an approach is likely to lead to improved
clinical care and should result in fewer patients requiring to
be managed on multiple medications.Competing interests
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